{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T05:56:04Z","timestamp":1718690164468},"reference-count":22,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2009,2,12]],"date-time":"2009-02-12T00:00:00Z","timestamp":1234396800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Gastro and Hepatol"],"published-print":{"date-parts":[[2009,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Background:\u2002<\/jats:bold> Anti\u2010tumor necrosis factor (TNF)\u2010alpha medications are effective in Crohn's Disease (CD) and efficacious in ulcerative colitis (UC). Adalimumab has been available through the Australian Pharmaceutical Benefits Scheme since August 2008, but clinical experience for inflammatory bowel disease (IBD) in Australia is limited.<\/jats:p><jats:p><jats:bold>Aims:\u2002<\/jats:bold> To determine adalimumab efficacy for IBD in the Australian setting.<\/jats:p><jats:p><jats:bold>Methods:\u2002<\/jats:bold> Crohn's disease or UC\/IBD unclassified (UC\/IBDU) patients received adalimumab after failure of disease control with conventional therapies or loss of control by infliximab. Response\/remission at 8 and 12\u2003weeks were determined by the Crohn's Disease Activity Index (CDAI) and Colitis Activity Index (CAI). All patients received 160\u2003mg (week 0), 80\u2003mg (week 2), followed by 40\u2003mg every\u2010other\u2010week (eow). Patients with a limited response at 8\u2003weeks were considered for weekly adalimumab.<\/jats:p><jats:p><jats:bold>Results:\u2002<\/jats:bold> Of 38 CD patients 86.8% (33\/38) had active luminal and 23.7% (9\/38) fistulising disease at inclusion. Response occurred in 81.8% and 84.4% of luminal CD at 8 and 12\u2003weeks, while 54.5% and 63.6% remitted respectively. 77.8% of fistulising CD responded and 55.6% remitted at 12\u2003weeks. Fifteen CD patients had previously lost response to infliximab, and 86.7% of these responded and 53.3% remitted at 12\u2003weeks. Of the seven UC\/IBDU patients 43% and 14% responded, while 29% and 0% remitted at 8 and 12\u2003weeks.<\/jats:p><jats:p><jats:bold>Conclusion:\u2002<\/jats:bold> In CD, adalimumab is as, if not more, effective in the clinical setting than in the trials, and is effective in patients with an attenuated response to infliximab. Its efficacy is not as good in UC, but this requires further clarification.<\/jats:p>","DOI":"10.1111\/j.1440-1746.2009.05786.x","type":"journal-article","created":{"date-parts":[[2009,2,12]],"date-time":"2009-02-12T07:05:28Z","timestamp":1234422328000},"page":"1252-1257","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Efficacy of adalimumab for the management of Inflammatory Bowel Disease in the Clinical Setting"],"prefix":"10.1111","volume":"24","author":[{"given":"Matthew W.","family":"Trinder","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian C.","family":"Lawrance","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,7,29]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2004.02.070"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199710093371502"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08512-4"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1445-5994.2001.00039.x"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2006.04739.x"},{"key":"e_1_2_5_7_2","first-page":"S57","article-title":"Efficacy and tolerability of weekly subcutaneous injections of the fully human anti\u2010TNF\u2010antibody D2E7 in patients with rheumatoid arthritis\u2010results of a phase I study","volume":"41","author":"Schattenkirchner M","year":"1998","journal-title":"Arthritis Rheum"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.21913"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.21306"},{"key":"e_1_2_5_10_2","first-page":"2563","article-title":"Adalimumab, a fully human anti tumor necrosis factor\u2010alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis)","volume":"30","author":"Furst D","year":"2003","journal-title":"J. Rheumatol"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.11.030"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.11.041"},{"key":"e_1_2_5_13_2","first-page":"111","article-title":"Expression of IL\u20108, TNF\u2010alpha and IFN\u2010gamma m\u2010RNA in ulcerative colitis, particularly in patients with inactive phase","volume":"46","author":"Masuda H","year":"1995","journal-title":"J. Clin. Lab. Immunol"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050516"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.14.2544"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1155\/2005\/269076"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.3109\/00365528909091339"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(76)80163-1"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.298.6666.82"},{"key":"e_1_2_5_20_2","first-page":"20","article-title":"Adalimumab rapidly induces clinical response and remission in patients with moderate to severe Crohn's disease who had secondary failure to infliximab therapy: results of the GAIN study","volume":"55","author":"Rutgeerts P","year":"2006","journal-title":"Gut"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2005.40647.x"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v13.i16.2328"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20155"}],"container-title":["Journal of Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1440-1746.2009.05786.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1440-1746.2009.05786.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T20:20:04Z","timestamp":1697314804000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1440-1746.2009.05786.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7]]},"references-count":22,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2009,7]]}},"alternative-id":["10.1111\/j.1440-1746.2009.05786.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1440-1746.2009.05786.x","archive":["Portico"],"relation":{},"ISSN":["0815-9319","1440-1746"],"issn-type":[{"value":"0815-9319","type":"print"},{"value":"1440-1746","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,7]]},"assertion":[{"value":"2009-07-29","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}